Kaia Health, a NYC-based digital therapeutics company, raised a $75m Series C funding round.
The round was led by an unnamed growth equity fund with participation from existing investors Optum Ventures, Eurazeo, capital300, Balderton Capital, Heartcore Capital, Symphony Ventures (the investment vehicle of golf legend Rory McIlroy) and A Round Capital.
The company, which has raised a total of $125m to date, intends to use the funds to grow its commercial team, accelerate product and partnership development and extend the offering within Europe.
Led by CEO, President, and Founder Konstantin Mehl, Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain, COPD and osteoarthritis. Working with experts across medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage their condition with digital alternatives from their home using devices they already own (i.e. smartphones and tablets). Kaia Health is a member of the Digital Therapeutics Alliance (DTA), an international non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. The company also has offices in Munich, Germany.